{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:08:44Z","timestamp":1764940124429,"version":"3.46.0"},"reference-count":5,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0055","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:22:58Z","timestamp":1756290178000},"source":"Crossref","is-referenced-by-count":0,"title":["Imatinib-Associated Hyperkeratotic Eruptions: A Rare Extensor Surface Manifestation"],"prefix":"10.4274","author":[{"given":"Vishu","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanshu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayush","family":"Kulshreshtha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5152\/eajm.2011.42","article-title":"Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia","volume":"43","author":"Albayrak","year":"2011","unstructured":"1. Albayrak M, Celebi H, Albayrak A, Can ES, Aslan V, Onec B, Coban I. Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia. Eurasian J Med. 2011;43:192-195.","journal-title":"Eurasian J Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3949\/ccjm.87a.19119","article-title":"Cutaneous adverse effects of biologic medications","volume":"87","author":"Pasadyn","year":"2020","unstructured":"2. Pasadyn SR, Knabel D, Fernandez AP, Warren CB. Cutaneous adverse effects of biologic medications. Cleve Clin J Med. 2020;87:288-299.","journal-title":"Cleve Clin J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ad.2013.01.009","article-title":"Adverse skin effects of imatinib, a ty-rosine kinase inhibitor","volume":"105","author":"Pretel-Irazabal","year":"2014","unstructured":"3. Pretel-Irazabal M, Tuneu-Valls A, Ormaechea-P\u00e9rez N. Adverse skin effects of imatinib, a ty-rosine kinase inhibitor. Actas Dermosifiliogr. 2014;105:655-662.","journal-title":"Actas Dermosifiliogr"},{"key":"ref3","unstructured":"4. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006;5:228-231."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to ty-rosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","unstructured":"5. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to ty-rosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386-395.","journal-title":"Dermatol Ther"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:04:23Z","timestamp":1764939863000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-74271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":5,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0055","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"type":"print","value":"1300-7777"},{"type":"electronic","value":"1308-5263"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}